country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-120764

Copy Link Print Information

PF-46396

PF-46396 is a potent HIV-1 inhibitor with an EC₅₀ value of 0.206 µM. PF-46396 shows antiviral activity. PF-46396 inhibits the processing of capsid (CA)/spacer peptide 1 (SP1) (p25) Gag precursor proteins and blocks maturation of the viral core particle.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS: 1207481-21-7
Fòrmula: C₂₇H₂₉F₃N₂O
Peso molecular:454.53

Almacenamiento:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (268 KB)

PF-46396 Chemical Structure

No. CAS: 1207481-21-7

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[1]

HIV-1

0.206 μM (EC₅₀)

Ver todos los productos específicos de isoformas HIV :

Cellular Effect

Cell Line	Type	Value	Description	References
CEM-SS	CC₅₀	20 μM Compound: PF-46396	Cytotoxicity against human CEM-SS cells after 6 days by XTT assay Cytotoxicity against human CEM-SS cells after 6 days by XTT assay	[PMID: 19805571]
CEM-SS	EC₅₀	>20 μM Compound: PF-46396	Antiviral activity against HIV1 RF infected in human CEM-SS cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay Antiviral activity against HIV1 RF infected in human CEM-SS cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay	[PMID: 19805571]
HeLa	EC₅₀	>10 μM Compound: PF-46396	Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	>10 μM Compound: PF-46396	Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	>3.2 μM Compound: PF-46396	Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.206 μM Compound: PF-46396	Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
MT2	CC₅₀	15 μM Compound: PF-46396	Cytotoxicity against human MT2 cells after 6 days by XTT assay Cytotoxicity against human MT2 cells after 6 days by XTT assay	[PMID: 19805571]
MT2	EC₅₀	>16 μM Compound: PF-46396	Antiviral activity against HIV1 RF infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay Antiviral activity against HIV1 RF infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay	[PMID: 19805571]
MT2	EC₅₀	0.017 μM Compound: PF-46396	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay	[PMID: 19805571]
MT2	EC₅₀	0.21 μM Compound: PF-46396	Antiviral activity against HIV1 92HT599 infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 5 days Antiviral activity against HIV1 92HT599 infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 5 days	[PMID: 19805571]
MT2	EC₅₀	0.24 μM Compound: PF-46396	Antiviral activity against HIV1 92HT594 infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 5 days Antiviral activity against HIV1 92HT594 infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 5 days	[PMID: 19805571]
MT2	EC₅₀	0.36 μM Compound: PF-46396	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity after 6 days by XTT assay	[PMID: 19805571]

Chemical Information

No. CAS 1207481-21-7
Peso molecular 454.53
Fòrmula C₂₇H₂₉F₃N₂O
SMILES

O=C1C(C(F)(F)F)=CC=CN1CC(NC2CC3=C(C=CC=C3)C2)C4=CC=C(C(C)(C)C)C=C4
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (268 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Blair WS, et al . New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother. 2009 Dec;53(12):5080-7. [Content Brief]

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto

Amount: USD 0.00

Actividad biológica
- Descripciòn
- IC₅₀ & Target
Chemical Information
Pureza y Documentación
Referencias

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

PF-46396

Ver todos los productos específicos de isoformas HIV

Actividad biológica

Chemical Information

Pureza y Documentación

Referencias

Calculators

Help & FAQs

PF-46396 Related Classifications

HY-120764 Related Classifications